Potential Therapeutic Role of Cannabinoid System in Alzheimer’s Disease: A Review

The purpose of the study was to investigate the role of the endocannabinoid system and the therapeutic potential benefits of cannabinoids in Alzheimer’s disease. The most frequent form of dementia in older individuals is Alzheimer's disease (AD), a progressive neurological ailment that gradually deprives people of their memory, cognitive abilities, and, ultimately, their ability to perform daily tasks. Alzheimer's disease is distinguished by a progressive deterioration in cognitive function, which includes a decline in memory, learning capacity, and thinking power. The human body's endocannabinoid system functions as a channel for cell communication. It is a neurotransmission system that is present in various regions of the body and tissues as well as assists in the control of a number of metabolic processes. Endocannabinoids, enzymes, and cannabinoid receptors all play a role in managing a variety of biological functions. In this review, we aimed to summarize the endocannabinoid system, the effect of beta-amyloid, tau-protein accumulation and neuroinflammation, potential therapeutic benefits of cannabinoids, current pre-clinical and clinical evidence for the potential therapeutic benefits, limitations, and challenges, and potential future research in the field. Emerging scientific data suggests that the ECS (Endocannabinoid system) is linked to neurodegenerative illnesses and that altering its tone may be a useful therapeutic strategy for the treatment of AD (Alzheimer’s disease).